Melatonin (Circadin®)

Assessment Status Full HTA Assessment
Drug Melatonin
Brand Circadin®
Indication Prolonged release melatonin (Circadin®) for the short-term treatment of primary insomnia.
Assessment Process
Full submission received from Applicant 01/08/2008
NCPE assessment completed 21/10/2008
NCPE assessment outcome Reimbursement not recommended.

Technical Summary

We believe that there is currently insufficient evidence to support the reimbursement of this product under the Community Drugs Schemes.